Improvement in appearance of keloids (hypertrophic scars), scleroderma, acne keloidalis nuchae,old burn scars, granuloma annulare, and related conditions with altered dermal matrix Subjects will be evaluated at weeks 1, 2, 4, and then at monthly intervals until the end of the study. [clinicaltrials_resource:072bbce5d24f297f30c92abfdda9277b]
A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Improvement in appearance of keloids (hypertrophic scars), scleroderma, acne keloidalis nuchae,old burn scars, granuloma annulare, and related conditions with altered dermal matrix Subjects will be evaluated at weeks 1, 2, 4, and then at monthly intervals until the end of the study. [clinicaltrials_resource:072bbce5d24f297f30c92abfdda9277b]
A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
Bio2RDF identifier
072bbce5d24f297f30c92abfdda9277b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:072bbce5d24f297f30c92abfdda9277b
measure [clinicaltrials_vocabulary:measure]
Improvement in appearance of k ...... ons with altered dermal matrix
time frame [clinicaltrials_vocabulary:time-frame]
Subjects will be evaluated at ...... ls until the end of the study.
description
A dose of up to 320 mJ/cm2 fro ...... 5 times per week for 16 weeks.
identifier
clinicaltrials_resource:072bbce5d24f297f30c92abfdda9277b
title
Improvement in appearance of k ...... ls until the end of the study.
@en
type
label
Improvement in appearance of k ...... bbce5d24f297f30c92abfdda9277b]
@en